Piramal Pharma expects FY 2027 to see a revival in growth 29.04.2026 18:45 Thehindubusinessline.com It posted a Rs ₹9 crore loss Q4 FY 26, impacted by an impairment cost of Rs ₹176 crore linked to assets under development
